Basel, Switzerland (ots/PRNewswire) - - New Treatment Option the First to Help Postmenopausal Women With Early Breast Cancer Remain Cancer-Free Following Adjuvant Tamoxifen Therapy Femara(R) (letrozole) is the first therapy approved by the U.S. Food and Drug Administration (FDA) for the extended adjuvant treatment of postmenopausal women with early breast ...
Shire Pharmaceuticals Group Plc
St Louis, Missouri (ots/PRNewswire) - Shire Pharmaceuticals Group plc (NASDAQ: SHPGY, LSE: SHP.L, TSE: SHQ CN) announced that long-term treatment with FOSRENOL(R) (lanthanum carbonate) for up to five years, shows no deterioration in bone health according to new data presented today for the first time at the ...
Vienna, Austria (ots/PRNewswire) - - Medical experts and patients call for early diagnosis to improve chances of cure According to leading oncologists, speaking today at the European Society for Medical Oncology, findings from the MOSAIC study represent a significant step forward in providing colon ...
Madrid (ots/PRNewswire) - PharmaMar today announced that Kahalalide F (KF), its marine-origin compound, has entered into Phase II trials for the treatment of patients with severe psoriasis. KF is currently undergoing Phase II clinical trials in various tumours: melanoma, non-small lung cancer and hepatocarcinoma. During the Phase I clinical trials on ...
Madrid (ots/PRNewswire) - The Zeltia Group (ZEL.MC) today reported financial results for the third quarter and the nine months ended September 30, 2004. Q3 Highlights Financial: - Group sales up 6.3% to Euro 63.7million (Euro 59.9 million 9M03) - Losses before interest and tax narrowed significantly to Euro 2.3 million (Euro 5.5 million 9M03) - R&D down by 28.9% to Euro 27.8 million reflecting a ...
Prague, Czech Republic (ots/PRNewswire) - - Patients call for better standards of care People with psoriasis are still being treated as social outcasts according to the results of a new international survey announced on World Psoriasis Day. This has led for calls from a leading patient advocate, Lars ...
Basel, Switzerland (ots/PRNewswire) - - New M3 selective receptor antagonist treatment for overactive bladder Novartis Pharma AG announced today that Emselex(R) (darifenacin hydrobromide), 7.5 mg and 15 mg, has been granted Marketing Authorization by the European Commission for the treatment of overactive bladder (OAB) in all 25 European member states as ...
Montreal, Canada (ots/PRNewswire) - Galileo Genomics announced today the completion of a panel of approximately 80,700 SNP markers covering 99.8% of the sequenced genome at a density optimised for the Quebec French Canadian Founder Population (QFP). This panel, known as the Quebec Linkage Disequilibrium Map ...
Espoo, Finland (ots/PRNewswire) - - Parkinson's Patients who Require the Start of Levodopa Therapy may be Eligible to Participate in This Study Orion Pharma and Novartis announced that they are launching STRIDE-PD (STalevo Reduction In Dyskinesia Evaluation). This major study in Parkinson's disease (PD) ...
Basel, Switzerland (ots/PRNewswire) - - Parkinson's Patients Who Require the Start of Levodopa Therapy May Be Eligible to Participate in This Study Novartis and Orion Pharma announced that they are launching STRIDE-PD (STalevo Reduction In Dyskinesia Evaluation). This major study in Parkinson's disease ...
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for tipranavir. Simultaneously the documentation was submitted to the FDA. Tipranavir is a non-peptidic protease inhibitor (NPPI) for ...
Basel, Switzerland (ots/PRNewswire) - Roche announced today that its innovative cancer drug, Avastin has received a positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP). The CHMP has recommended that Avastin (bevacizumab) in combination with intravenous ...
Ann Arbor, Michigan (ots/PRNewswire) - - Aastrom's Proprietary TRCs to be Utilized to Build New Bone Tissue for Dental Implants -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM), and the Institut de Terapia Regenerativa Tissular (ITRT) announced today that they have initiated patient enrollment in a clinical ...
Bothell, Washington and Indianapolis, Indiana (ots/PRNewswire) - - Third Quarter 2004 U.S. sales of Cialis exceed US$70 million - Lilly ICOS LLC (Lilly ICOS) (NYSE: LLY and Nasdaq: ICOS) is releasing its financial results for the three and nine months ended September 30, 2004. Worldwide sales of Cialis(R) (tadalafil) in the third quarter of 2004 were ...
Basel, Switzerland (ots/PRNewswire) - Key figures First nine months Nine months 2004 Nine months 2003 % Change USD m % of sales USD m % of sales USD lc[1] Sales 20 669 18 134 14 9 Pharmaceutical 11 641 ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced today the appointment of Patrice R. Debregeas to its board of directors. As Chairman, CEO and President of Ethypharm S.A, the leading drug delivery company in Europe, Mr. Debregeas brings extensive international experience in the pharmaceutical ...
Buenos Aires, Argentina (ots/PRNewswire) - -- Additional Analysis Shows Couples Agree Cialis Improves Erectile Function in Men with ED and Increases Satisfaction with Sexual Experience -- An international study conducted in 21 countries showed that 82 percent of men with ED who were treated with 20 mg ...
Ann Arbor, Michigan (ots/PRNewswire) - Aastrom Biosciences, Inc. (NasdaqSC: ASTM) and the Institut de Terapia Regenerativa Tissular (ITRT) announced today that their clinical trial in Barcelona, Spain will be expanded based on initial results from the first phase of patient treatments. The trial involved 5 ...
Copenhagen, Denmark (ots/PRNewswire) - Tamas Bartfai, Ph.D., is the director of the Harold L. Dorris Neurological Research Center at The Scripps Research Institute, La Jolla, CA. In addition, he holds the Harold L. Dorris Chair in Neuroscience. Professor Bartfai is former head of central nervous system research at Hoffman-La Roche where he served as Senior Vice ...
Lausanne (ots) - IMD has been ranked as one of the world's Top 5 business schools by two of the most prestigious MBA ranking bodies: BusinessWeek and The Economist Intelligence Unit (EIU). As previously announced the 2004 Wall Street Journal survey of corporate recruiters ranked IMD as the No. 1 international ...
Basel, Switzerland (ots/PRNewswire) - Today, HIV drug Fuzeon (enfuvirtide or T-20) was awarded the 2004 International Prix Galien for the most innovative new medicine. Fuzeon was selected out of 12 major new drugs in all therapeutic areas which each won national awards. Since 1970 Roche has won a total of 24 ...
Wolters Kluwer Health, Pharma Solutions
Chester, England (ots/PRNewswire) - - Accepts Prestigious 2004 'Investors in People' Award Wolters Kluwer Health, Pharma Solutions business unit today announced that Adis International was named a 2004 "Investor in People" by the Investors in People UK Recognition Panel. The London-based organization assesses corporate business practices against a national ...
Madrid (ots/PRNewswire) - The United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to Yondelis in the indication of Soft Tissue Sarcoma (STS). The sponsor of this application in the US is our partner Johnson & Johnson Pharmaceutical Research & Development. The European Commission (E.C.) already granted Orphan Drug status for this ...
Lausanne (ots) - IMD, one of the world's top business schools, announces that its Zurich Alumni Club and Accenture Zürich, a leading worldwide strategy consultancy, have successfully completed a pro bono consulting project with UNICEF Switzerland (Baumackerstrasse 24, 8050 Zürich), world-renowned supporter of children's causes in the United Nations member ...
Indianapolis (ots/PRNewswire) - - New Analysis Showed Teriparatide Prevented Fracture Risk Associated with Increasing Number, Severity of Osteoporotic Fractures Data presented at the American Society for Bone and Mineral Research (ASBMR) 26th annual meeting in Seattle, Wash., showed that the number and severity of prior fractures are strong predictors of future fractures in postmenopausal women with ...
Indianapolis (ots/PRNewswire) - Data presented at the 26th annual meeting of the American Society for Bone and Mineral Research (ASBMR), Seattle, Wash., shows that the ability of teriparatide to prevent fractures remained consistent regardless of pretreatment bone turnover status.(1) Bone is living tissue that constantly regenerates itself by breaking down and ...
Madrid, Spain (ots/PRNewswire) - PharmaMar announced today that Aplidin(R), its second marine-derived compound in Phase II clinical development, has been granted orphan drug status by the United States (US) Food and Drug Administration (FDA), for the treatment of Multiple Myeloma (MM). This is the second orphan drug designation granted to Aplidin by the FDA. The ...
Dayton, Ohio (ots/PRNewswire) - Robbins & Myers, Inc. (NYSE: RBN) announced today that its Board of Directors approved a regular quarterly cash dividend payment of US $.055 per share that is payable on October 29, 2004 to shareholders of record as of October 15, 2004. The Company also announced that its annual shareholders' meeting will be held December 8, 2004 in Dayton, Ohio, with record date set of October 15, ...
Geneva, Switzerland (ots/PRNewswire) - PharmaMar presented data from six studies, four of which were from pharmacogenomics research projects at the EORTC-NCI-AACR[1] International Conference on Molecular Targets and Cancer Therapeutics, held in Geneva, Switzerland, from 28 September to 1 October 2004. ...
Montreal (ots/PRNewswire) - ProMetic Life Sciences (PLI:TSX) announced today the administrative reorganisation of its communications and business development structure. By implementing these changes, the Company is focusing its business development activities in key markets providing optimal growth opportunities namely in the United States, Europe, Asia and the Middle East. ProMetic can better achieve this goal ...